Cytomegalovirus (CMV) Testing Market: By Diagnosis (Serologic test, Polymerase Chain Reaction (PCR) Test, and Others), By Diseases (Retinitis, Pneumonia, Gastrointestinal Ulcers, Encephalitis, and Others), By Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, and Other), By End-User (Hospitals, Specialty Clinics, Homecare, and Others) and Geography

Cytomegalovirus Testing Market size was valued at USD 251.9 million in 2022 and is expected to reach USD 420.6 million by 2029, growing at a CAGR of 8.7% from 2024 to 2030. The CMV blood test is performed to detect current active CMV infection or past CMV infection in people who are at risk for reactivation of infection. These people include organ transplant recipients and those with a suppressed immune system. The test may also be performed to detect CMV infection in newborns. The market of Cytomegalovirus (CMV) treatment is subjected to change as per government regulation and licensing authority, the market observed a decline in BPS values due to inefficacy in patients and severe immunosuppression and disseminated diseases.

In the past years, the rise in the coronavirus pandemic and the limitation of cytomegalovirus treatment have shown negative effects on the market. FDA is continuously improvised for approval of new cytomegalovirus treatment which regains the market. The increasing prevalence of cytomegalovirus infection across the world, according to the Centres for Disease Control and Prevention (CDC), in the United States nearly 1 in 3 children have been infected with CMV by age 5 years, and over half of adults have been infected with CMV by age 40 which is the major factor that drives the market. It is predicted that an increase in several research and development activities, and a rise in infants infected in utero (congenital CMV infection) have very low birth weight premature infants suffer the most, and rapidly developing healthcare infrastructure across the world creates various opportunities in the market. Additionally, the high cost of treatment obstructs market growth, and the lack of medical professionals in emerging countries are the major restraints for the growth of the CMV market. Geographically, North America held the major market share in 2022 and is expected to dominate the cytomegalovirus (CMV) market in the forecasted years.

Cytomegalovirus Testing Market Key Developments:

• In May 2022, Cipla launched a real-time RT-PCR test kit for COVID-19. The RT Direct test protocol does not require any RNA extraction process, which makes it faster and helps deliver results in 45 minutes, the company added.
• In March 2022, Kaneka launched KANEKA RT-PCR Kit “SARS-CoV-2 (L452R/E484Q/E484K/N501Y)”, which can detect four variants simultaneously, and KANEKA RT-PCR Kit “SARS-CoV-2 (Omicron/Delta). which can detect the Delta and Omicron variants of COVID-19. These Kaneka products are being used at major sporting events and for pre-travel PCR testing, as well as in medical facilities and testing centers. These products make it possible to quickly test large numbers of samples.